 Biocept Inc NASDAQ:BIOC FRA:B003 has announced a collaboration with Quest Diagnostics Inc NYSE:DGX FRA:QDI to provide laboratory testing services to Quest patients for its Target Selector NGS-based liquid biopsy targeted lung cancer panel. Biocept said both companies expect the service to be available to Quests providers and patients in the fourth quarter of 2021. 